Philochem-Bracco agreement opens new path for cancer diagnosis

Philochem, a subsidiary of the Philogen group, and Bracco Imaging announce “a licensing and collaboration agreement for the development and commercialization of an organic small molecule for imaging applications with a proven ability to selectively visualize and diagnose a variety of metastatic solid tumors. thus paving the way for a new approach to cancer diagnosis “. Bracco and Philochem’s goal is to “lead the way in the development of cutting-edge technologies for the discovery and optimization of small ligands that enable unprecedented specificity and sensitivity for solid tumor imaging.” Philogen and Bracco, both with headquarters in Italy – recalls a note – are active globally in the pharmaceutical and biotech sectors. “We are extremely pleased to establish a new collaboration with Bracco Imaging, a world leader in the field of diagnostic imaging – says Dario Neri, member of the Board of Philochem and managing director of the Philogen group – This new collaboration will focus on development and commercialization of a small molecule for applications in imaging, which has the ambition to improve diagnosis, staging and monitoring of treatment response for cancer patients. Both companies are committed to developing the product in order to make it available to patients who could benefit from it. “” We are excited about this collaboration with Philochem, leader in the discovery and development of new pharmaceutical and biopharmaceutical products – declared Fulvio Renoldi Bracco, Vice President and CEO of Bracco Imaging – A partnership that demonstrates Bracco’s commitment in creating long-term value in med imaging ico. Over the years, Bracco has built a portfolio of leading products across all diagnostic modalities, and continues to invest in innovation to shape the future of precision imaging and improve people’s lives. “